A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder
- PMID:17689532
- DOI: 10.1016/j.expneurol.2007.06.013
A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder
Abstract
We compared the binding profiles of medications potentially useful in the treatment of involuntary emotional expression disorder at twenty-six binding sites in rat brain tissue membranes. Sites were chosen based on likelihood of being target sites for the mechanism of action of the agents in treating the disorder or their likelihood in producing side effects experienced by patients treated with psychoactive agents. We used radioligand binding assays employing the most selective labeled ligands available for sites of interest. Concentrations of labeled ligand were used at or below the K(i) value of the ligand for the target site. Compounds were initially screened at 1 muM. For compounds that competed for greater than 20-30% of specific binding at target sites of interest, full concentration curves were constructed. Dextromethorphan, amitriptyline and fluoxetine competed for binding to sigma(1) receptors and to serotonin transporters with high to moderate affinity. Of the target sites tested, these are the most likely to contribute to the therapeutic benefit of the various agents. In addition, all three drugs showed some activity at alpha(2) and 5-HT(1B/D) sites. Of the drugs tested, dextromethorphan bound to the fewest sites unlikely to be target sites. Although the mechanism of action of dextromethorphan or any drug that has been used in the treatment of involuntary emotional expression disorder is currently unknown, our data support that the affinity of the drug for sigma(1) receptors is consistent with its possible action through this receptor type in controlling symptoms of the disorder.
Similar articles
- Allosteric modulation of 5-HT(1A) receptors by zinc: Binding studies.Barrondo S, Sallés J.Barrondo S, et al.Neuropharmacology. 2009 Feb;56(2):455-62. doi: 10.1016/j.neuropharm.2008.09.018. Epub 2008 Oct 14.Neuropharmacology. 2009.PMID:18951909
- Effects of combined treatment with cognitive enhancer memantine and antidepressant fluoxetine on CYP2D2 metabolic activity in rats.Zendulka O, Jurica J, Zahradnikova L, Sabova M, Sulcova A.Zendulka O, et al.Neuro Endocrinol Lett. 2011;32(5):727-32.Neuro Endocrinol Lett. 2011.PMID:22167136
- Comparison of [(3)H]-(2S,4R)-4-methylglutamate and [(3)H]D-aspartate as ligands for binding and autoradiographic analyses of glutamate transporters.Apricò K, Beart PM, Crawford D, O'shea RD.Apricò K, et al.Neurochem Int. 2007 Dec;51(8):507-16. doi: 10.1016/j.neuint.2007.05.011. Epub 2007 May 31.Neurochem Int. 2007.PMID:17590480
- Therapeutic use of dextromethorphan: key learnings from treatment of pseudobulbar affect.Miller A, Panitch H.Miller A, et al.J Neurol Sci. 2007 Aug 15;259(1-2):67-73. doi: 10.1016/j.jns.2006.06.030. Epub 2007 Apr 16.J Neurol Sci. 2007.PMID:17433820Review.
- Slow accumulation of psychotropic substances in the human brain. Relationship to therapeutic latency of neuroleptic and antidepressant drugs?Kornhuber J, Retz W, Riederer P.Kornhuber J, et al.J Neural Transm Suppl. 1995;46:315-23.J Neural Transm Suppl. 1995.PMID:8821068Review.
Cited by
- Treatment Resistant Depression with Loss of Antidepressant Response: Rapid-Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule.Lauterbach EC.Lauterbach EC.Psychopharmacol Bull. 2016 Aug 15;46(2):53-58.Psychopharmacol Bull. 2016.PMID:27738380Free PMC article.
- Sigma Receptors as Endoplasmic Reticulum Stress "Gatekeepers" and their Modulators as Emerging New Weapons in the Fight Against Cancer.Tesei A, Cortesi M, Zamagni A, Arienti C, Pignatta S, Zanoni M, Paolillo M, Curti D, Rui M, Rossi D, Collina S.Tesei A, et al.Front Pharmacol. 2018 Jul 10;9:711. doi: 10.3389/fphar.2018.00711. eCollection 2018.Front Pharmacol. 2018.PMID:30042674Free PMC article.Review.
- Dextromethorphan/quinidine: in pseudobulbar affect.Garnock-Jones KP.Garnock-Jones KP.CNS Drugs. 2011 May;25(5):435-45. doi: 10.2165/11207260-000000000-00000.CNS Drugs. 2011.PMID:21476614Review.
- The epidemiology and pathophysiology of pseudobulbar affect and its association with neurodegeneration.King RR, Reiss JP.King RR, et al.Degener Neurol Neuromuscul Dis. 2013 May 27;3:23-31. doi: 10.2147/DNND.S34160. eCollection 2013.Degener Neurol Neuromuscul Dis. 2013.PMID:30890891Free PMC article.Review.
- A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19.Zhou Y, Liu Y, Gupta S, Paramo MI, Hou Y, Mao C, Luo Y, Judd J, Wierbowski S, Bertolotti M, Nerkar M, Jehi L, Drayman N, Nicolaescu V, Gula H, Tay S, Randall G, Lis JT, Feschotte C, Erzurum SC, Cheng F, Yu H.Zhou Y, et al.Res Sq [Preprint]. 2022 Jun 7:rs.3.rs-1354127. doi: 10.21203/rs.3.rs-1354127/v2.Res Sq. 2022.Update in:Nat Biotechnol. 2023 Jan;41(1):128-139. doi: 10.1038/s41587-022-01474-0.PMID:35677070Free PMC article.Updated.Preprint.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical